RecruitingACTRN12612000052831

Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)

Can early response measurement by FDG PET/CT in patients with metastatic colorectal cancer receiving third-line therapy with cetuximab predict the progression-free survival and overall survival?

Sponsor

Chang Gung Memorial Hospital

Enrollment

30 participants

Start Date

Jul 5, 2011

Study Type

Observational

Conditions

Metastatic colorectal cancer receiving third-line therapy with cetuximab

Summary

The primary objective of the current study is to determine if the change in parameters acquired by FDG-PET/CT before and 4 weeks after the initiation of cetuximab therapy is predictive of the progression-free survival (PFS) in the third-line treatment of patients with metastatic colorectal cancer

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study examines whether changes on a PET/CT scan after 4 weeks of starting the drug cetuximab can predict how well it will work for people with metastatic colorectal cancer (bowel cancer that has spread). PET/CT scans show the metabolic activity of tumours. If early scan changes can reliably predict treatment success, doctors could know sooner whether a treatment is working and make better decisions faster. You may be eligible if: - You are 18 years or older - You have metastatic colorectal cancer with at least one measurable tumour - Your tumour has been tested and is confirmed to have normal (wild-type) K-ras - You have previously received both irinotecan-based and oxaliplatin-based chemotherapy You may NOT be eligible if: - You have had another primary cancer in the last 3 years - You have previously been treated with cetuximab or panitumumab Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

FDG PET/CT imaging on a dedicated PET/CT system (Siemens Biograph) is to be performed at baseline, and after one cycle and four cycles of Cetuximab therapy. CT is to be performed every 3 months to determine the progression-free survival. Patients will be followed up for at least one year. The FDG PET/CT imaging is non-invasive but requires the patients to fast for 6 hours before the examination and takes up to 3-hour stay.

Locations(1)

Taiwan, Province Of China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000052831